Hidden bacteria presents a substantial risk of antimicrobial resistance in hospital patients

Peer-Reviewed Publication

Amsterdam University Medical Centers

 

Amsterdam, The Netherlands (January 30, 2023) — Carriers of a specific hidden bacteria have a 14% chance of developing an antibiotic resistant infection with 30 days of hospitalisation, according to researchers from Amsterdam UMC. Researchers studied patients who unknowingly carried the multi-resistant Gram-negative bacteria, a major cause of urinary tract infections and sepsis, and found that almost 1 in 7 developed an infection that very few antibiotics could treat. The results have been published in The Lancet Infectious Diseases.

People can carry antibiotic resistant bacteria unknowingly and without any effects or symptoms. These bacteria are often found in the intestines, in the mouth or on the skin. Carrying these bacteria only becomes a problem if patients develop an infection, which can happen during hospitalisation. If so, it is difficult to treat. And that complicates the treatment those who have been hospitalized for another reason.

Researchers from Amsterdam UMC’s Department of Medical Microbiology and Infection Prevention set out to determine: what is the chance that a carrier of resistant bacteria develops an infection during admission? This knowledge could help hospitals stay alert to antibiotic resistant infections. To answer this question, the researchers dug into the medical literature.

 

‚Dirty‘ and ‚clean‘ surgery 

The study showed that the risk of infection with multidrug-resistant Gram-negative bacteria is on average 14% within 30 days in hospitalized patients. For certain types of bacteria from this group, this chance is as high 19%. This is a significant risk. In comparison infection rates after surgery vary from 1% to around 20%, dependent on the procedure. After a so-called ‚dirty surgery‘ – an operation in a body area with a lot of bacteria, for example intestinal surgery – the chance of an infection is 18-20%. After a ‚clean operation‘ – surgery in a sterile area of the body – it is much lower, around 1-3% within 30 days.

 

Comparing Bacteria

This research not only exposes the risk of infections, but also facilitates the comparison of different types of resistant bacteria. It also provides tools for comparing the risk to different types of patients: for example, the risk of infection for patients in intensive care differs from that for patients in nursing wards, or for patients with blood cancer. It is therefore important to note that most of the patients in the studies involved were seriously ill. These patients are more likely to get infections.

 

Breaking Resistance 

Antimicrobial resistance is an increasing problem worldwide. This resistance makes some infections increasingly difficult to treat, for which only few and more expensive antibiotics are available. In some countries, there are already problems with infections with bacteria that are so resistant that no treatment is possible. This has led the World Health Organisation to name antimicrobial resistance as one of the ten global public health „threats facing humanity“. With antimicrobial resistance to common antibiotics used to treat, for example urinary tract infections reaching over 90% in some cases. This makes research into the possibilities of stopping carriership of resistant bacteria in the intestine, in order to prevent untreatable infections, even more timely and important.

—-

 

Journal: The Lancet Infectious Diseases

DOI: 10.1016/S1473-3099

Method of Research: Meta-analysis

Subject of Research: People

Article Title: Incidence of infection with multidrug-resistant Gramnegative bacteria and vancomycin-resistant Enterococci in carriers: a systematic review and meta-regression analysis

Article Publication Date: 30-Jan-2023

 

COI Statement

MJGTV reports research grants from Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics and speaker fees from or consulting for, or both, Alb Fils Kliniken, Arderypharm, Astellas Pharma, Basilea, Bio-Mérieux, DaVolterra, Farmak International Holding, Ferring, Gilead Sciences, Immunic, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, and SocraTec R&D. All other authors declare no competing interests.

 

 


Amsterdam University Medical Centers, 30.01.2023 (tB).

Schlagwörter: , , , ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…